Netherlands-based pharmaceutical company Synthon’s 40mg/ml of glatiramer acetate has received regulatory approval for the treatment of relapsing forms of multiple sclerosis (MS) in Europe.

MS is an unpredictable, often disabling disease of the central nervous system that disturbs the flow of information within the brain, and between the brain and body.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The approval followed the company’s successful completion of the decentralised procedures for pre-filled syringe glatiramer acetate at 40mg/ml.

The Synthon treatment can be administered three times a week and is a therapeutically equivalent version of Teva Pharmaceutical Industries’ originator medicine Copaxone at 40mg.

The company has received regulatory clearance for glatiramer acetate at 40mg/ml in all 27 member states

Synthon received regulatory clearance in all 27 member states of the European Union, including Iceland, Liechtenstein, and Norway.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Synthon chief executive officer Jacques Lemmens said: “We are very pleased with this approval. It allows us to make an affordable version of the 40mg/ml dosage strength of glatiramer acetate available to MS patients in Europe.”

“We are very pleased with this approval. It allows us to make an affordable version of the 40mg/ml dosage strength of glatiramer acetate available to MS patients in Europe.”

In April last year, Synthon’s glatiramer acetate injection at 20mg/ml received approval in Europe for the treatment of relapsing-remitting multiple sclerosis (RRMS) and is already available in several European markets.

RRMS is the most common form of MS in which the patient suffers from clear episodes of inflammatory activity known as relapses, followed by remission.

Synthon is Mylan’s European partner of glatiramer acetate injection products at 20mg/ml and 40mg/ml.

Mylan has exclusive distribution and supply rights for the products for Germany, France, Spain, Portugal, Belgium, Italy, the Netherlands, the UK, Ireland, Switzerland, Greece, Denmark, Sweden, Norway, Finland, Cyprus and Malta.